Nordea nostaa kehotustaan 30.10.24: OSTA.
”We upgrade our recommendation to Buy (Hold) with a SOTP-based fair value of EUR 52.0. We believe that Nubeqa could be one of the biggest products in
prostate cancer and reach USD 4.3bn in global revenues. This should help Orion reach a CAGR of 9% for 2023-28E and grow its EBIT by 10% for the same period.”
Kommentti: Jos Nubeqa myy yli EUR 3bn, rojaltikin nousee diilin mukaan 20->25 %
